Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Sell
14
KLDO Quote, Financials, Valuation and Earnings
Last price:
$0.0000
Seasonality move
:
-21.5%
Day range:
$0.0001 - $0.0001
52-week range:
$0.0000 - $0.3500
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.00x
P/B ratio:
0.00x
Volume:
5.5K
Avg. volume:
7.6K
1-year change:
9900%
Market cap:
$4.3K
Revenue:
--
EPS (TTM):
--
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target UpsideNo price target exists because of limited analyst coverage.
-
Price Target DownsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Kaleido Biosciences, Inc. has 21999900% upside to fair value with a price target of -- per share.
KLDO vs. S&P 500
-
Over the past 5 trading days, Kaleido Biosciences, Inc. has underperformed the S&P 500 by -0.1% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Kaleido Biosciences, Inc. does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Kaleido Biosciences, Inc. has grown year-over-year revenues for 1 quarter straight. In the most recent quarter Kaleido Biosciences, Inc. reported revenues of --.
Earnings Growth
-
Kaleido Biosciences, Inc. has grown year-over-year earnings for 9 quarters straight. In the most recent quarter Kaleido Biosciences, Inc. reported earnings per share of --.
Enterprise value:
-16.8M
EV / Invested capital:
--
Price / LTM sales:
0.00x
EV / EBIT:
--
EV / Revenue:
-15.20x
PEG ratio (5yr expected):
--
EV / Free cash flow:
0.21x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2020-12-31 | 2021-12-31 | |
| Income Statement | ||||||
| Revenue | -- | $975K | $1.1M | $243K | $492K | |
| Gross Profit | -$1.3M | -$369K | -$112K | -- | -$112K | |
| Operating Income | -$86.7M | -$78.9M | -$87.7M | -$19.3M | -$19.7M | |
| EBITDA | -$85.3M | -$77.1M | -$85.3M | -$18.7M | -$19.1M | |
| Diluted EPS | -$3.77 | -$2.44 | -$2.16 | -$0.56 | -$0.48 | |
| Period Ending | 2017-12-31 | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $28.6M | $76.2M | $73.3M | $48.7M | $42.3M | |
| Total Assets | $30.7M | $85.3M | $82.3M | $59.6M | $50.3M | |
| Current Liabilities | $3.9M | $11.3M | $10.4M | $16.7M | $29.7M | |
| Total Liabilities | $21.9M | $28.3M | $33.4M | $39.1M | $39.7M | |
| Total Equity | $8.8M | $57M | $48.9M | $20.5M | $10.6M | |
| Total Debt | $17.6M | $15.6M | $20.5M | $21M | $21.7M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2020-12-31 | 2021-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$75.8M | -$61.6M | -$77.1M | -$11.4M | -$17.2M | |
| Cash From Investing | -$3.6M | -$4M | -$691K | -$662K | $2K | |
| Cash From Financing | $74.6M | $40.5M | $70.1M | $3.7M | -$25K | |
| Free Cash Flow | -$79.4M | -$65.6M | -$78.2M | -$12M | -$17.6M | |
KLDO
Sector
Market Cap
$4.3K
$27.9M
Price % of 52-Week High
0.03%
51.04%
Dividend Yield
0%
0%
Shareholder Yield
--
-1.49%
1-Year Price Total Return
9900%
-16.66%
Beta (5-Year)
34.073
0.516
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$0.0001
200-day SMA
Sell
Level
$0.0041
Bollinger Bands (100)
Sell
Level
-0.0338 - 0.0462
Chaikin Money Flow
Sell
Level
--
20-day SMA
Sell
Level
$0.0103
Relative Strength Index (RSI14)
Sell
Level
48.1521
ADX Line
Neutral
Level
6.6327
Williams %R
Buy
Level
-99.9479
50-day SMA
Sell
Level
$0.0043
MACD (12, 26)
Sell
Level
0.0000
25-day Aroon Oscillator
Buy
Level
4
On Balance Volume
Neutral
Level
5.1K
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (4)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Kaleido Biosciences, Inc. is a clinical-stage healthcare company, which engages in the provision of healthcare services. It focuses on leveraging the microbiome organ to treat disease and improve human health. The firm offers microbiome metabolic therapies (MMT), which are designed to modulate the metabolic output and profile of the microbiome by driving the function and composition of the organ's existing microbes. The company was founded by Geoffrey von Maltzahn and Noubar B. Afeyan on January 27, 2015 and is headquartered in Lexington, MA.
Stock Forecast FAQ
In the current month, KLDO has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The KLDO average analyst price target in the past 3 months is --.
-
Where Will Kaleido Biosciences, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Kaleido Biosciences, Inc. share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Kaleido Biosciences, Inc.?
Analysts are divided on their view about Kaleido Biosciences, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Kaleido Biosciences, Inc. is a Sell and believe this share price will drop from its current level to --.
-
What Is Kaleido Biosciences, Inc.'s Price Target?
The price target for Kaleido Biosciences, Inc. over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is KLDO A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Kaleido Biosciences, Inc. is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of KLDO?
You can purchase shares of Kaleido Biosciences, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Kaleido Biosciences, Inc. shares.
-
What Is The Kaleido Biosciences, Inc. Share Price Today?
Kaleido Biosciences, Inc. was last trading at $0.0000 per share. This represents the most recent stock quote for Kaleido Biosciences, Inc.. Yesterday, Kaleido Biosciences, Inc. closed at $0.0001 per share.
-
How To Buy Kaleido Biosciences, Inc. Stock Online?
In order to purchase Kaleido Biosciences, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get KLDO Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
KLDO
Sector
P/E ratio
--
23.85x
PEG ratio
--
-0.01x
P/B ratio
0.00x
1.81x
Price / LTM sales
0.00x
1.58x
Growth Metrics
KLDO
Sector
Revenue growth
--
4.62%
Earnings growth
--
10.7%
Revenue (5-year growth)
--
6.5%
Earnings forecast
--
-$0.21
Profitability
KLDO
Sector
Profitability FY 2025
--
$3.6M
Return on invested capital
--
-31.87%
Return on assets
--
-28.18%
Return on equity
--
-37.63%
Earnings Date
Last Earnings Date
May
17
Next Earnings Date
Dec
23
Estimated Next Earnings Date
Mar
24
Balance Sheet
KLDO
Sector
Total cash
--
$26.4M
Short term investments
--
$25.7M
Total assets
--
$76.9M
Long term debt
--
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire Hathaway Stock Undervalued?
Berkshire Hathaway (NYSE:BRK.A,BRK.B) has undershot the market this year, returning…
Is Oracle Stock Undervalued?
Shares of Oracle (NYSE:ORCL) rocketed higher earlier this year when…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
57
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 38x
Alerts
Sell
1
LW alert for Dec 22
Lamb Weston Holdings, Inc. [LW] is down 2.59% over the past day.
Buy
54
BMRN alert for Dec 22
BioMarin Pharmaceutical, Inc. [BMRN] is down 3.03% over the past day.
Buy
82
RKLB alert for Dec 22
Rocket Lab Corp. [RKLB] is up 9.97% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
